Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination with docetaxel in treating patients who have metastatic prostate cancer that is refractory to hormone therapy.

Key facts

Study ID

NCT00005857

Run by

City of Hope Medical Center

Starts

2000-08-01

Expected to finish

2002-10-01

Last updated by the study team

2011-10-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Cancer Center and Beckman Research Institute, City of Hope — Duarte, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States
• St. Elizabeth's Medical Center of Boston — Brighton, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.